| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-400-164-7117 18317119277 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:1,3,5-Trimethyl-2-tosylbenzene
CAS:5184-64-5
Purity:98% Package:10mg;25mg;50mg;100mg;250mg;1g Remarks:BD416253
|
Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- manufacturers
- ESI-05
-
- $33.00 / 2mg
-
2026-01-29
- CAS:5184-64-5
- Min. Order:
- Purity: 98.00%
- Supply Ability: 10g
|
| | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- Basic information |
| Product Name: | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- | | Synonyms: | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]-;1,3,5-Trimethyl-2-[(4-methylphenyl)sulfonyl]benzene;MESITYL P-TOLYL SULFONE;ESI-05;ESI-05
(ESI05);1,3,5-trimethyl-2-tosylbenzene;NSC 116966;ESI-05 >=98% (HPLC) | | CAS: | 5184-64-5 | | MF: | C16H18O2S | | MW: | 274.38 | | EINECS: | | | Product Categories: | | | Mol File: | 5184-64-5.mol | ![Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- Structure](CAS/20200401/GIF/5184-64-5.gif) |
| | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- Chemical Properties |
| Melting point | 119-120 °C | | Boiling point | 426.7±45.0 °C(Predicted) | | density | 1.129±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: soluble | | form | powder | | color | white to beige |
| | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- Usage And Synthesis |
| Uses | ESI-05 has been used to study the effect of protein exchange directly activated by cAMP 2 on traumatic brain injury. | | Biochem/physiol Actions | ESI-05 is a selective inhibitor against cAMP-regulated guanine nucleotide exhange factor (GEF) EPAC2 (Exchange factor directly activated by cAMP 2) activation by targeting an EPAC2-specific allosteric site at the interface of the two cAMP-binding domains. ESI-05 inhibits EAPC2, but not EPAC1 or PKA, activation by cAMP in a highly potent (IC50 = 430 nM; 25 μM cAMP) and cAMP-competitive manner in cell-free assays, and suppresses cAMP analog 007-AM-induced cellular Rap1 activation in EPAC2-, but not EPAC1-, expressing HEK293 transfectants. | | in vivo | ESI-05 (2, 4, and 8 mg/kg) decreases neuronal apoptosis by inhibiting the p38/BIM pathway in vivo[2]. | Animal Model: | Intracranial hemorrhage (ICH) model[2] | | Dosage: | 2, 4, and 8 mg/kg | | Administration: | | | Result: | Decreased the apoptosis rate of nerve cells in the cortex accompanied by a corresponding decrease in the protein expression of phosphorylated p38, Bcl-2like protein 11 (BIM), and caspase-3. |
| | storage | Store at RT |
| | Benzene,1,3,5-trimethyl-2-[(4-methylphenyl)sulfonyl]- Preparation Products And Raw materials |
|